FOLFIRI方案治疗常规含奥沙利铂方案化疗失败的转移性结直肠癌疗效观察  

Efficacy of FOLFIRI Regimen in the Metastatic Colorectal Cancer Patients Refractory to Conventional Chemotherapy with Oxaliplatin

作　　者：黄治虎[1] 李小刚 张群[1] 赵璐[1] 丁宁[1] 宋永波[1] 田庆[1] 周世勇[3] 

机构地区：[1]皖北煤电集团总医院肿瘤化疗科,安徽宿州234011 [2]中国核工业集团202厂医院 [3]天津医科大学附属肿瘤医院内一科

出　　处：《包头医学院学报》2012年第3期41-44,共4页Journal of Baotou Medical College

摘　　要：目的:观察FOLFIRI方案治疗经常规含奥沙利铂方案化疗失败的转移性结直肠癌的近期疗效及不良反应。方法:32例晚期转移性结直肠癌使用FOLFIRI方案化疗,伊立替康(Irinotecan)180 mg/m2、亚叶酸钙(CF)200 mg/m2静脉滴注1～2 d,氟脲嘧啶(5-FU)400 mg/m2静脉推注1～2 d,然后5-FU 600 mg/m2持续静脉滴注22 h,每2周重复,2次为1个周期,共行4～6个周期。结果:32例中有12例部分缓解(PR),无CR病人,该方案总有效率(CR+PR)为37.5%,中位疾病进展时间(TTP)为8.3个月,中位总生存期为13.5个月;主要的不良反应为迟发性腹泻和中性粒细胞减少,Ⅲ+Ⅳ度发生率分别为25.0%(8/32)和40.7%(13/32)。结论:FOLFIRI方案对常规含奥沙利铂方案化疗失败的晚期转移性结直肠癌疗效较好,不良反应轻微,主要不良反应为迟发性腹泻和中性粒细胞减少,患者耐受性较好。Objective： To observe the efficacy and adverse reactions of FOLFIRI regimen in the metastatic colorectal cancer patients refractory to conventional chemotherapy with oxaliplatin. Methods： Thirty two cases with advanced metastatic colorectal cancer were treated with FOLFIRI regimen, which consisted of intravenous infusion irinotecan 180 mg/m2 dl ＋ leucovorin 200 mg/m2 dl - 2, intravenous injection 5 - FU 400 mg/m2 dl - 2, and followed by 22 hours continuous intravenous infusion 5 - FU 600 mg/m2, every 2 weeks as a period,2 times as a cycle, altogether 4 -6 cycles. Results： Of the 32 patients, 12 had a partial response （PR）, and no one had complete response （CR）. The total effective rate （CR ＋ PR） was 37.5 %, the medi- an time to progression was 8.3 months, the median overall survival was 13.5 months. The main adverse reactions were delayed diarrhea and neutropenia, grade III and IV rates were 25.0 % （8/32） and 40.6 % （13/32）, respectively. Conclusion： FOL- FIRI regimen is effective and well tolerated in the metastatic colorectal cancer patients refractory to conventional chemotherapy with oxaliplatin. The main adverse reactions are delayed diarrhea and neutropenia.

关 键 词：伊立替康 结直肠癌 疗效 不良反应 

分 类 号：R735.3[医药卫生—肿瘤]